RxDoctor Payments Data

Jessica Wood, APRN

Nurse Practitioner · Jonesboro, ARNPI 1124432455

Payments from drug & device makers

$1,108in general payments, 2019–2025

Across 64 payments — averaging $17.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$414
  • Astellas Pharma US Inc$94
  • AstraZeneca$63
  • Amgen$59
  • Novo Nordisk$57
  • GSK$54
  • plus $367 from 11 others

What the payments were for

  • Food & beverage$1,01492%
  • Education$948%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,108 in reported general payments places this provider in the 75th percentile of 697 nurse practitioner providers in Arkansas.

See all nurse practitioner providers in Arkansas

Medicare billing

Part B allowed, 2024
$19,796
Medicare patients
72
Services billed
952

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide198$210,843
JardianceEmpagliflozin83$68,885
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog45$53,599
LinzessLinaclotide52$34,219
EliquisApixaban37$31,381
GlyxambiEmpagliflozin/Linagliptin20$26,695
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$23,426
XareltoRivaroxaban20$16,659
Emgality PenGalcanezumab-Gnlm17$16,069
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$11,365
OzempicSemaglutide12$11,193
BelsomraSuvorexant20$8,877
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen229$6,622
BrilintaTicagrelor14$6,343
SantylCollagenase Clostridium Hist.17$6,319

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$27$210,843198 claims
Boehringer IngelheimJardiance, Glyxambi$31$95,580103 claims
AbbVieLinzess$414$34,21952 claims
GSKTrelegy Ellipta$54$23,42634 claims
AstraZenecaBreztri Aerosphere, Brilinta, Symbicort$63$19,99643 claims
Johnson & JohnsonXarelto$53$16,65920 claims
Novo NordiskOzempic$57$11,19312 claims
Esperion Therapeutics, Inc.Nexlizet$53$4,92812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 697 nurse practitioner providers in Arkansas.

Other nurse practitioner in Jonesboro

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →